What a country platform could look like
A worked exemplar showing how development fees create the asset and manufacturing and licensing sustain it. The country is not identified: this is a model, not a live engagement. All figures in USD.
Read this first. Every figure below is an illustrative management projection prepared for discussion. It is not a commitment, an audited forecast, an offer, or investment advice. Technical, regulatory, procurement, foreign-exchange and financing outcomes may change results materially. Manufacturing revenue is company turnover, not a government or shareholder return; any return analysis must use distributable cash flow after cost of goods, operating costs, taxes, reinvestment and ownership allocations.
Business model
Develop
Create the asset
Milestone-funded design, candidate production, bioanalysis, scale-up and filing readiness.
Manufacture
Sustain it
Clinical trial lot, then scale to production with income from off-take agreements.
Expand
Extend the network
Regional sublicensing, technology transfer and platform royalties.
R&D sources and uses, exemplar
| Cost component | Basis | Amount |
|---|---|---|
| Personnel | 6 full-time equivalents for 8 months | $1,488,000 |
| Consumables | $50,000 per month average | $400,000 |
| Equipment | Incubation, processing and QC | $450,000 |
| Facility | 8 months | $160,000 |
| Regulatory and IP | Filing and counsel | $150,000 |
| Training | Embedded programme | $75,000 |
| Total planned spend | $2,723,000 | |
−$273,000Base-funding gap against planned spend. Must be committed before launch.
+$227,000Headroom if every contingent incentive pays.
$500,000Regulatory incentive pool, contingent, not guaranteed.
Five-year base case, exemplar
| Year | Revenue | Opex | EBITDA | Margin |
|---|---|---|---|---|
| 2027 | $1,050,000 | $4,180,000 | ($3,130,000) | -298% |
| 2028 | $13,930,000 | $10,070,000 | $3,860,000 | 28% |
| 2029 | $21,690,000 | $14,200,000 | $7,490,000 | 35% |
| 2030 | $29,050,000 | $18,230,000 | $10,820,000 | 37% |
| 2031 | $32,400,000 | $21,670,000 | $10,730,000 | 33% |
| Five-year | $98,120,000 | $68,350,000 | $29,770,000 | 30% |
The dose ramp underlying this case is a management assumption dependent on approval, purchase agreements, capacity, yield and working capital.
Sensitivity
| Scenario | Modelled effect | The diligence question it raises |
|---|---|---|
| Trial application delayed 6 months | Five-year NPV approximately 15 percent lower | Is procurement or sublicensing possible before approval? |
| Cost of goods falls 20 percent | Five-year EBITDA approximately 26 percent higher | What yield and automation evidence supports the per-dose cost? |
| Global licence secured | Large milestone upside | Are deal values probability-weighted and genuinely comparable? |
| Outbreak escalation | Emergency-volume upside | Can the facility, supply chain and approval route support the volume? |
| FX and inflation | Cost and cash volatility | What is hedged, local-currency denominated, or indexed? |
Deliberately left out. The prospectus flags its own items to revise before investor use, and this page honours that list. It does not describe demand as guaranteed, does not present a multiple-of-investment government return on gross revenue, and does not name any country or publish any ownership split. Those belong behind a partner login, after the capital total, IP percentages, Phase 2 funding and sublicence allocations have been reconciled.
Transaction readiness
Converting a projection into an investable data room needs six workstreams.
- 1. TechnicalYield, purity, stability, dose definition, scale-up, backup constructs
- 2. RegulatoryNational pathway, trial design, WHO route, milestone evidence standards
- 3. CommercialDemand, pricing, buyers, advance purchases, sublicence pipeline
- 4. FinancialIntegrated monthly model, working capital, tax, FX, capex, scenarios
- 5. Legal and IPBackground and foreground IP, equity, royalties, access, dispute rules
- 6. GovernanceDecision authority, multisig, quorum, custody, audit, termination rights